IOVA - Iovance Biotherapeutics' Amtagvi: Innovative Therapy Financial Strain (Rating Downgrade)
2024-05-13 11:06:56 ET
Summary
- Iovance's new TIL therapy, Amtagvi, has launched but with modest Q1 revenue amidst substantial operational costs.
- Enrollment has reached over 100 patients, showing a promising start, although logistical challenges persist.
- Financially, Iovance has a short-term cash runway, risking future capital raises and possible dilution.
- Recommendation: Hold Iovance shares; suitable for speculative segment of a diversified, conservative portfolio.
Evaluating Iovance Amidst Amtagvi's Launch and Financial Pressures
Iovance Biotherapeutics' ( IOVA ) stock continues its rollercoaster ride. Its stock traded down 18% on Friday, the day after it reported Q1 earnings ....
Iovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)